Opioid Use Disorder (OUD) Market Size, Share & Industry Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2019-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Opioid Use Disorder (OUD) Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Opioid Use Disorder (OUD) market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Opioid Use Disorder (OUD) market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Opioid Use Disorder (OUD) Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Opioid Use Disorder (OUD) Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Opioid Use Disorder (OUD) Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Diverse Product Portfolio by Indivior PLC and Alkermes to Propel Their Share
The key players dominating the market are Indivior PLC and Alkermes due to their diverse product portfolio across the globe. In terms of revenue, Indivior PLC holds dominance owing to its blockbuster product suboxone, which is indicated for the treatment of opioid dependence. The significant upscale of the product across the globe is anticipated to propel the growth of the market during the forecast period. Additionally, various initiatives taken by the company such as national campaigns conducted to create awareness related to new products for the treatment of OUD is also propelling the market growth. Alkermes is considered as the prominent market player owing to revenue generation by its blockbuster product named Vivitrol, containing naltrexone for the prevention of opioid dependence by encouraging opioid detoxification.

However, some of the key players such as Purdue Pharma and others have entered the different regions across the globe even after discontinuation of their product oxycontin in the U.S and Canada. Therefore, the market is expected to experience tough competition during the forecast period.

LIST OF KEY COMPANIES PROFILED:

  
Indivior PLC
  
Alkermes
  
Orexo US, Inc.
  
Titan Pharmaceuticals Inc.
  
TEVA PHARMACEUTICALS USA, INC
  
Mallinckrodt.
  
BioDelivery Sciences International Inc.
  
Mylan
  
Pfizer Inc.
  
Hikma Pharmaceuticals
  
Camurus

KEY INDUSTRY DEVELOPMENTS:

December 2018 “Sandoz Inc and Pear Therapeutics obtained FDA clearance for first prescription digital therapeutic named reSET-O for the treatment of opioid use disorder. reSET-O is to be used to increase retention of patients with OUD in outpatient settings by providing cognitive behavioral therapy.

November 2017 -US FDA approved Sublocade product by Indivior PLC, which is injectable buprenorphine and is used for the treatment of moderate to severe opioid use disorder.

REPORT COVERAGE

The opioid use disorder market report provides a detailed analysis of the market and focuses on key aspects such as leading companies, drug class of Opioid use disorder, route of administration, and others. Besides this, the report provides key insights into the market trends and highlights major industry developments such as mergers, acquisitions, and collaborations, new product launches, statistics of opioid use disorder, and pipeline analysis.  In addition to this, the report also focuses on the major driving factors and restraints that are influencing the market growth over the course of the period.

Report Scope & Segmentation

 Segmentation

By Drug Class

  
Buprenorphine
  
Methadone
  
Naltrexone

By Route of Administration

  
Oral
  
Parenteral

By Distribution Channel

  
Hospitals Pharmacies
  
Retail Pharmacies & Stores
  
Online Pharmacies

By Geography

  
North America (U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  
Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
  
Rest of the World